In a smaller study of NSCLC patients (n = 39) treated with αPD‐1, higher baseline plasma sPD‐L1 (>3.36 ng/mL) correlated with shorter mOS (7.20 months vs. not reached at 14 months) and shorter time to treatment failure (1.48 vs. 5.36 months).42 Here, SPDL1 is linked to non-small cell lung carcinoma.